quizartinib,midostaurin
daiichi sankyo,novartis
['quantum-first']
1) comparing ratify to quantum-first is a bit tricky! you can t compare median os (75 vs 31 months) or 4-year os (51% vs ? maybe 45%) as quantum had older patients 60-75 allowed (ratify only less than 60) yrs and only itd (which do worse than tkd included in ratify) #eha2022 
Director-Heme Early Therapeutics & Leader-Leukemia/Myeloid Research @Yale. Personal views. I tweet on cancer, travel, food & soccer. COI: https://t.co/6XkF8CmtrK